» ITV NEWS COVERAGE- Are Drug Companies doing enough to tackle Duchenne? Action Duchenne

» ITV NEWS COVERAGE- Are Drug Companies doing enough to tackle Duchenne? Action Duchenne: "On the 17th October, Action Duchenne’s CEO Paul Lenihan was asked to appear on ITV News to provide further background to Carl Tilson’s discussions with Summit plc.

Paul emphasised throughout his interview that Action Duchenne is committed to early and free access to all new Duchenne medicines regardless of funding and cost and that all parties should combine to influence the legislative processes – processes that currently could delay such early access to medicine. We remain committed to this line and hope this article will add to the debate surrounding the Medical Innovation Bill.

To see the interview in full, click here."



'via Blog this'

PPMD Submits Letter to FDA Regarding Latest Sarepta Update - PPMD Community

PPMD Submits Letter to FDA Regarding Latest Sarepta Update - PPMD Community: "Today’s press release and investor call from Sarepta have sent a ripple of angst and sadness through our community. Moments ago, PPMD sent a letter to the FDA that reflects our organization’s belief that safety and rigor have been demonstrated throughout this process. Further, we believe that any strengthening of data packages that causes delays (as is now being requested by the FDA, as articulated in today’s press release and call) should ensure a streamlined, more expeditious approval process for follow-on exons."



'via Blog this'

» Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy Action Duchenne

» Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy Action Duchenne: "Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy"



'via Blog this'